

C50: Malignant neoplasm of breast

Mortality

n = 63 859
311 events




Figure 1

C61: Malignant neoplasm of prostate

Mortality

n = 54 042
256 events




Figure 2

C50: Malignant neoplasm of breast
Mortality among prevalent cases

n = 1536 (prevalent C50)
130 events (death from C50)




Figure 3

C61: Malignant neoplasm of prostate

Mortality among prevalent cases

n = 584 (prevalent C61)
55 events (death from C61)




Figure 4

C50: Malignant neoplasm of breast (311 e vents)
Mortality risk





Figure 5a

C50: Malignant neoplasm of breast (311 e vents)
Mortality


Age at blood sampling

- ◇ 61–70
- ⊠ 53–61
- ◆ 39–53




Additional adjustments

- ◇ Assessment center, BMI and smoking status
- Assessment center



Short vs. long term risk

- ◇ 3–10 years from blood sampling
- Within 3 years from blood sampling



Hazard ratio (95% CI),
per 1-SD increment in multibiomarker score

Figure 5b

C61: Malignant neoplasm of prostate (254 events)
Mortality risk





Figure 6a

C61: Malignant neoplasm of prostate (254 events)
Mortality


Age at blood sampling

- ◊ 61–71
- ⊗ 53–61
- ◆ 39–53




Additional adjustments

- ◊ Assessment center, BMI and smoking status
- Assessment center



Short vs. long term risk

- ◊ 3–10 years from blood sampling
- Within 3 years from blood sampling



Hazard ratio (95% CI),
per 1-SD increment in multibiomarker score

Figure 6b